文拉法辛缓释剂和帕罗西汀治疗惊恐障碍的随机对照研究

目的:比较文拉法辛缓释剂和帕罗西汀治疗惊恐障碍的有效性和安全性。方法:将73例符合CCMD-3R的惊恐障碍病人随机分为2组,分别给予文拉法辛(38例,初始剂量75 mg·d~(-1))和帕罗西汀(35例,初始剂量10 mg·d~(-1))。采用惊恐症状评定量表(PASS)、汉密尔顿焦虑量表(HAMA)、临床总体印象量表(CGI)和不良反应量表(TESS)分别在治疗前,治疗后wk 2、4、8末各评定1次,并进行对比分析。结果:2组间在治疗后wk 2、4末PASS、HAMA、CGI评分有显著差异(P<0.05);在wk 8末2组间差异无显著意义(P>0.05);文拉法辛组PASS、HAMA、CGI评分在治疗后wk 2末比治疗前明显降低(P<0.05),在wk 4、8末有进一步改善(P<0.01);帕罗西汀组PASS、HAMA、CGI评分在治疗后wk 4、8末与治疗前相比均降分明显(P<0.01)。2组不良反应发生率无显著差异。结论:文拉法辛是一种快速有效且安全性较高的治疗惊恐障碍的药物。

A randomized controlled trial of venlafaxine extended release and paroxetine in patients with panic disorder

AIM:To assess the efficacy and safety of venlafaxine extended release in the treatment of panic disorder.METHODS:Seventy-three patients met with CCMD-3R criteria for panic disorder were randomly allocated to two groups and were treated with venlafaxine extended release(38 patients)or paroxetine (35 patients).The curative effects were assessed by PASS,HAMA,CGI and TESS before treatment and at the end of wk 2,4 and 8 of the trial,respectively.RESULTS:There was significant difference in PASS,HAMA and CGI at the end of wk 2,4 after the treatment between two groups(P<0.05),and there was no significant difference at the end of wk 8(P>0.05).PASS,HAMA and CGI in venlafaxine group decreased at the end of wk 2(P<0.05),and wk 4,8(P>0.01).PASS,HAMA and CGI in paroxetine group decreased at the end of wk 4,8(P<0.01).There was no significant difference of the adverse drug reactions between the two groups.CONCLUSION:Venlafaxine is a fast,effective and safe drug in the treatment of panic disorder.